Hepatitis C virus infection and liver failure in patients undergoing allogeneic bone marrow transplantation

A. Locasciulli, A. Bacigalupo, M. T. VanLint, D. Cavalletto, P. Pontisso, M. Testa, G. Masera, H. M. Shulman, B. Portmann, A. Alberti

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The role of hepatitis C virus (HCV) infection in severe liver failure (LF) following bone marrow transplantation is still uncertain. We therefore decided to determine the presence of HCV-RNA in 31 patients who died of severe LF after BMT and in 26 matched BMT controls who did not develop LF. HCV-RNA was identified by polymerase chain reaction and anti-HCV by second generation enzyme-linked immunoassay and by 4-band recombinant immunoblotting assay in serum samples obtained before and after BMT. Biochemical and clinical parameters of liver disease were obtained by reviewing clinical records. LF developed at a median interval of 80 days (20-570) from transplantation and was clinically assessed as VOD (n = 7), liver GVHD (n = 5) or hepatitis (n = 19). HCV-RNA was detected, respectively, in 15/31 (48%) and in 12/26 (46%) of LF patients and controls (P = 0.9). Conversely, the risk of dying of LF was 62% and 53% (P = 0.5) respectively, for HCV-RNA positive and negative patients. Anti-HCV profile did not correlate with viremia, nor with type of liver disease. These findings indicate that, despite a 47% prevalence of HCV infection in our series, HCV-RNA positivity was neither a predictor of VOD nor a marker for life-threatening liver disease.

Original languageEnglish
Pages (from-to)407-411
Number of pages5
JournalBone Marrow Transplantation
Volume16
Issue number3
Publication statusPublished - 1995

Fingerprint

Homologous Transplantation
Liver Failure
Virus Diseases
Bone Marrow Transplantation
Hepacivirus
RNA
Liver Diseases
Viremia
Immunoenzyme Techniques
Immunoblotting
Hepatitis
Transplantation
Polymerase Chain Reaction
Liver
Serum

Keywords

  • BMT
  • HCV infection
  • Liver failure

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Locasciulli, A., Bacigalupo, A., VanLint, M. T., Cavalletto, D., Pontisso, P., Testa, M., ... Alberti, A. (1995). Hepatitis C virus infection and liver failure in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplantation, 16(3), 407-411.

Hepatitis C virus infection and liver failure in patients undergoing allogeneic bone marrow transplantation. / Locasciulli, A.; Bacigalupo, A.; VanLint, M. T.; Cavalletto, D.; Pontisso, P.; Testa, M.; Masera, G.; Shulman, H. M.; Portmann, B.; Alberti, A.

In: Bone Marrow Transplantation, Vol. 16, No. 3, 1995, p. 407-411.

Research output: Contribution to journalArticle

Locasciulli, A, Bacigalupo, A, VanLint, MT, Cavalletto, D, Pontisso, P, Testa, M, Masera, G, Shulman, HM, Portmann, B & Alberti, A 1995, 'Hepatitis C virus infection and liver failure in patients undergoing allogeneic bone marrow transplantation', Bone Marrow Transplantation, vol. 16, no. 3, pp. 407-411.
Locasciulli, A. ; Bacigalupo, A. ; VanLint, M. T. ; Cavalletto, D. ; Pontisso, P. ; Testa, M. ; Masera, G. ; Shulman, H. M. ; Portmann, B. ; Alberti, A. / Hepatitis C virus infection and liver failure in patients undergoing allogeneic bone marrow transplantation. In: Bone Marrow Transplantation. 1995 ; Vol. 16, No. 3. pp. 407-411.
@article{155e85e8337544caab9359280c3873b5,
title = "Hepatitis C virus infection and liver failure in patients undergoing allogeneic bone marrow transplantation",
abstract = "The role of hepatitis C virus (HCV) infection in severe liver failure (LF) following bone marrow transplantation is still uncertain. We therefore decided to determine the presence of HCV-RNA in 31 patients who died of severe LF after BMT and in 26 matched BMT controls who did not develop LF. HCV-RNA was identified by polymerase chain reaction and anti-HCV by second generation enzyme-linked immunoassay and by 4-band recombinant immunoblotting assay in serum samples obtained before and after BMT. Biochemical and clinical parameters of liver disease were obtained by reviewing clinical records. LF developed at a median interval of 80 days (20-570) from transplantation and was clinically assessed as VOD (n = 7), liver GVHD (n = 5) or hepatitis (n = 19). HCV-RNA was detected, respectively, in 15/31 (48{\%}) and in 12/26 (46{\%}) of LF patients and controls (P = 0.9). Conversely, the risk of dying of LF was 62{\%} and 53{\%} (P = 0.5) respectively, for HCV-RNA positive and negative patients. Anti-HCV profile did not correlate with viremia, nor with type of liver disease. These findings indicate that, despite a 47{\%} prevalence of HCV infection in our series, HCV-RNA positivity was neither a predictor of VOD nor a marker for life-threatening liver disease.",
keywords = "BMT, HCV infection, Liver failure",
author = "A. Locasciulli and A. Bacigalupo and VanLint, {M. T.} and D. Cavalletto and P. Pontisso and M. Testa and G. Masera and Shulman, {H. M.} and B. Portmann and A. Alberti",
year = "1995",
language = "English",
volume = "16",
pages = "407--411",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Hepatitis C virus infection and liver failure in patients undergoing allogeneic bone marrow transplantation

AU - Locasciulli, A.

AU - Bacigalupo, A.

AU - VanLint, M. T.

AU - Cavalletto, D.

AU - Pontisso, P.

AU - Testa, M.

AU - Masera, G.

AU - Shulman, H. M.

AU - Portmann, B.

AU - Alberti, A.

PY - 1995

Y1 - 1995

N2 - The role of hepatitis C virus (HCV) infection in severe liver failure (LF) following bone marrow transplantation is still uncertain. We therefore decided to determine the presence of HCV-RNA in 31 patients who died of severe LF after BMT and in 26 matched BMT controls who did not develop LF. HCV-RNA was identified by polymerase chain reaction and anti-HCV by second generation enzyme-linked immunoassay and by 4-band recombinant immunoblotting assay in serum samples obtained before and after BMT. Biochemical and clinical parameters of liver disease were obtained by reviewing clinical records. LF developed at a median interval of 80 days (20-570) from transplantation and was clinically assessed as VOD (n = 7), liver GVHD (n = 5) or hepatitis (n = 19). HCV-RNA was detected, respectively, in 15/31 (48%) and in 12/26 (46%) of LF patients and controls (P = 0.9). Conversely, the risk of dying of LF was 62% and 53% (P = 0.5) respectively, for HCV-RNA positive and negative patients. Anti-HCV profile did not correlate with viremia, nor with type of liver disease. These findings indicate that, despite a 47% prevalence of HCV infection in our series, HCV-RNA positivity was neither a predictor of VOD nor a marker for life-threatening liver disease.

AB - The role of hepatitis C virus (HCV) infection in severe liver failure (LF) following bone marrow transplantation is still uncertain. We therefore decided to determine the presence of HCV-RNA in 31 patients who died of severe LF after BMT and in 26 matched BMT controls who did not develop LF. HCV-RNA was identified by polymerase chain reaction and anti-HCV by second generation enzyme-linked immunoassay and by 4-band recombinant immunoblotting assay in serum samples obtained before and after BMT. Biochemical and clinical parameters of liver disease were obtained by reviewing clinical records. LF developed at a median interval of 80 days (20-570) from transplantation and was clinically assessed as VOD (n = 7), liver GVHD (n = 5) or hepatitis (n = 19). HCV-RNA was detected, respectively, in 15/31 (48%) and in 12/26 (46%) of LF patients and controls (P = 0.9). Conversely, the risk of dying of LF was 62% and 53% (P = 0.5) respectively, for HCV-RNA positive and negative patients. Anti-HCV profile did not correlate with viremia, nor with type of liver disease. These findings indicate that, despite a 47% prevalence of HCV infection in our series, HCV-RNA positivity was neither a predictor of VOD nor a marker for life-threatening liver disease.

KW - BMT

KW - HCV infection

KW - Liver failure

UR - http://www.scopus.com/inward/record.url?scp=0029152031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029152031&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 407

EP - 411

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -